Clinical Trials Browser

OTHER × Pancreatic Neoplasms × Specimen Handling × Clear all

NCT06651580 2026-03-04

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

Gastrointestinal

Pancreatic Neoplasms, Pancreatitis, Pancreatitis, Chronic

NCT04975516 2026-03-03

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06958328 2026-02-02

LAP100

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06073431 2026-01-09

LOTUS

GastrointestinalThoracic

Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07326150 2026-01-08

Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer

Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07226856 2025-12-22

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06744595 2025-12-12

Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer

Phase NA Enrolling by invitation

Gastrointestinal

Pancreatic Neoplasms

NCT06423326 2025-07-30

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07089940 2025-07-29

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Phase EARLY_PHASE1 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06454383 2025-04-10

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05523154 2025-02-18

"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures

Phase NA Terminated

8 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT06206876 2025-01-17

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT04067960 2024-08-14

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer

Phase EARLY_PHASE1 Completed

CNSGastrointestinalGenitourinaryGynecologic

Brain Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02001337 2019-11-07

EXPAND

Gastrointestinal

Diabetes Mellitus, Pancreatic Neoplasms